lated after treatment. The top-ranked down-regulated genes in the treated cell lines included those related to receptor and kinase activity, signal transduction, apoptosis, RNA processing, protein metabolism and transport, cell cycle and transcription. A smaller number of genes were up-regulated in the cell lines after treatment and included genes involved in apoptosis, transcription, development and differentiation. Conclusions: These results demonstrate that the expression of the genes involved in cell proliferation and apoptosis as well as RNA, DNA and protein metabolism were affected by SN-38. The impact of certain genes on colorectal cancer development needs to be further evaluated; however, these results could serve as a basis for further studies in order to find targets for irinotecan treatment.
though the incidence in Sweden has increased during the past 40 years, the mortality rate has remained constant due to early diagnosis, improvement in surgical skills and more efficient anti-cancer drugs. Almost 50% of all CRC patients will subsequently develop metastasis, which is the leading cause of CRC-related deaths. Metastatic CRC is treated with surgery whenever possible; however, systemic treatment is the main focus [2] . Many treatments are ineffective with a high frequency of chemo-resistance. It is therefore of great importance to find novel biological markers for treatment of metastatic CRC, which will also improve control of local recurrence that eventually leads to metastatic disease.
Irinotecan is a topoisomerase 1 (topo-1) inhibitor given to patients with refractory metastatic colorectal tumours and has been proved to significantly improve the overall survival of patients resistant to 5-fluorouracil treatment [3, 4] . The drug has been used clinically for several years, although studies are on-going in order to improve the regimen [5] [6] [7] . Irinotecan is converted by carboxylesterase to the active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38), which is 100-to 1,000-fold more active compared to the pro-drug [8, 9] . The cytotoxicity derives from the binding between SN-38 and the DNA-associated nuclear enzyme topo-1 which leads to inhibition of topo-1 and, as a consequence, single stranded (ss) DNA breaks. This mechanism becomes irreversible, leading to double stranded (ds) DNA breaks over time and subsequently to cell death and to tumour regression [10] . Irinotecan has been proven to exert cytotoxicity in a wide range of solid tumours including breast, colon, prostate and lung [11] .
The formation of dsDNA breaks disrupts the cell cycle and triggers G2/M arrest. The status of cell cycle regulator p53 is of significance for the response of cell death. Wild-type p53 leads to long-term cell cycle arrest, i.e. cellular senescence, while mutated p53 gives premature mitosis, mitotic catastrophe and apoptosis.
In our previous study, the colon cancer cell lines KM12C, KM12SM and KM12l4a were treated with the topo-1 inhibitor SN-38. The results showed that the SN-38 treatment induced not only cell cycle arrest, but also apoptosis. Protein expression studies determined that the pathways including apoptosis-associated proteins like Bax and survivin were affected by the drug treatment [12] . In the survey to identify potential biological markers for treatment, it is of interest to further investigate the biological effect of SN-38 on cell lines. In the present study, the gene expression profiles of the cell lines treated with SN-38 were examined by microarray analysis.
Materials and Methods

Materials and Drug Treatments
KM12C, KM12SM and KM12L4a human colon carcinoma cell lines were kindly provided by Prof. I.J. Fidler (M.D. Anderson Cancer Center, Houston, Tex., USA). The parental cell line KM12C was originally established from a colon carcinoma Dukes' B2. Cells from this cell line were repeatedly injected into the cecum and spleen in athymic mice, to form 2 new cell lines KM12L4a and KM12L4a, both with high metastatic potential.
The cell lines were maintained in Eagle's MEM medium supplemented with 10% heat-inactivated foetal bovine serum, sodium pyruvate, vitamins and a cocktail of penicillin and streptomycin at 37 ° C in 5% carbon dioxide (Gibco; Invitrogen, Paisley, UK). Cells growing exponentially were harvested when a confluency of 80% was achieved.
The prodrug irinotecan is converted by carboxylesterases to its active metabolite SN-38. We used the metabolite SN-38 (Aventis Pharma, Paris, France) for drug treatment and it was diluted to a stock solution of 50 mg/ml in dimethyl sulfoxide (DMSO). The stock solution was kept in -20 ° C and diluted in medium to appropriate concentrations before use. For all experiments, cells were trypsinated, counted, plated in duplicates in 10-cm Petri dishes (Corning, Oneonta, N.Y., USA) with a seeding density of 0.33 ! 10 6 cells/cm 2 and then incubated for 24 h to allow the cells to adhere. After 24 h, cells were treated with SN-38 (2.5 g/ml) and harvested after 24 and 48 h, respectively. This protocol was originally designed in previous study by Wallin et al. [12] and in this paper the cellular phenotypes of the cell lines are more clearly depicted. Treated cells and controls were washed 3 ! in ice-cold PBS and then scraped into 5 ml of Trizol (Invitrogen, Carlsbad, Calif. USA). The cell lysates were kept in -70 ° C until RNA was isolated. Untreated cells incubated with a DMSO concentration in the medium equivalent to the concentration SN-38 was diluted in, were used as controls for all experiments (referred to as 'untreated controls' in the text).
Preparation of RNA and Microarray
The RNA isolation were performed using Trizol (Invitrogen) followed by the RNeasy Midi kit (Qiagen, Valencia, Calif., USA), according to the manufacturers' manuals. The reference RNA used was the Universal Human Reference RNA (Stratagene, La Jolla, Calif., USA). Both RNA samples and reference were transcribed into cDNA and labelled with Cy3 and Cy5 using the CyScribe TM cDNA post-labelling kit (Amersham Biosciences, Amersham, UK). The RNA were annealed with Anchored oligo(dT) primer and an extension reaction was performed using CyScript TM reverse transcriptase. When synthesised, amino allyldUTP was incorporated into the cDNA. The remaining intact RNA was degraded by NaOH and the amino allyl-modified firststrand cDNA was purified using EtOH precipitation. In order to get a labelled cDNA probe, the purified amino allyl-modified cDNA was coupled with an excess of reactive CyDye TM NHS esters (Amersham Bioscences). Samples (treated cells and untreated controls) were coupled to Cy3 and reference cDNA to Cy5, then purified with the Cyscribe GFX purification kit to maximise the signal to noise ratio. The samples were pooled together and blocking reagents, Poly d(A) (Amersham Biosciences), Yeast tRNA (Sigma) and Human Cot-1 DNA (Invitrogen Life Technologies) were added as well before it was vacuum-dried to a pellet. Hybri-disation was performed manually using the Pronto! TM universal hybridization kit (Corning Life Sciences, N.Y., USA), according to the manufacturer's instructions. The vacuum-dried pellet was resuspended in the Pronto! hybridization solution and applied to the slides. The slides were washed with the enclosed washing solutions and sealed in a Corning hybridization chamber at 42° for 18 h.
The human 70-mer oligonucleotide array consisted of ϳ 27,000 spots with oligonucleotides supplied by the Operon V2 27k clones. The slides were manufactured at the Swegene DNA Microarray Resource Center, Department of Oncology, Lund University, Sweden.
Image and Data Analysis
All slides were scanned using an Agilent DNA microarray scanner (Agilent technologies, Palo Alto, Calif., USA) at 10 m resolution, setting the PMT (photo multiplier tube) in both channels (red at 635 nm and green at 532 nm) to 100%. The images were analysed using GenePix TM Pro 4.1.1.4 (Axon Instruments, Union City, Calif., USA) which automatically aligned grids, associated spots with their reporter IDs and gene names and flagged spots 'found' or 'not found' depending of their quality. The automatic gridding and flagging was manually verified to eliminate artefacts and bad spots from subsequent analyses. GenePix Pro was then used to extract foreground and background pixel intensities for each spot into a GenePix result file which was then imported into the web-based BioArray Software Environment (BASE; http://base.thep.lu.se [13] ) used for further data management and analyses.
Background corrections, filtering, transformations and statistical analyses were all performed uniformly on the array data within BASE. Background correction was performed by subtracting the median of the background pixel intensities from the median of the foreground or spot intensities in both channels for all spots. Preliminary quality filters were set to eliminate spots flagged 'not found' or 'bad', spots with diameters less than or equal to 55 m, spots with signal intensities less than or equal to zero and signal saturated spots in both channels. The background-corrected log-transformed intensity values were then normalised using the global LOWESS method where intensitydependant adjustments (LOWESS fits) were performed to compensate for dye bias [14] . Data from replicate spots on the same array were merged in a weighted fashion, as previously described [15] . The data were centred and transformed using the error-model in order to reduce the importance of poor-quality spots in later analysis steps [16] . Additional filters were applied to eliminate spots with multiple cluster hits, spots representing ESTs without any known function and spots with missing LocusLink identifiers. Furthermore, only spots with a minimum standard deviation (SD) of 0.2 and 65% presence across all hybridizations were used in the hierarchical cluster analysis. Unsupervised agglomerative hierarchical clustering based on the Pearson correlation distance metric was carried out using the freely available TMeV software (www.tm4.org/mev.html [17] ) on the 5,915 spots that passed the various above-mentioned filter criteria. This was carried out in order to group together the control and treated cell lines harvested at different time points based on their similarities in gene expression profiles.
A supervised analysis was performed to identify the genes that differed in expression levels between the 6 treated cell lines and the 6 untreated control cell lines. The 5,915 genes were ranked on their Golub-scores or discriminative weight [18] . The relative expression ratios of each gene in the treated and untreated subclasses were used to calculate the mean (m) and the standard deviation ( ) for that particular gene across all the samples within each of the 2 subclasses. By using the mean and standard deviation calculated, each gene was assigned a discriminative score:
where m 1 and m 0 are the mean values and 1 and 0 are the standard deviations for subclasses 1 and 0, respectively. A high Golub-score suggests minor variation in gene expression within the subclass, but large variation between the subclasses. A random permutation test with 1,000 permutations was performed so as to assess the discriminating power of the score to differentiate the treated and untreated subclasses. For each score, the average number of genes in a permutation list above that score was divided by the number of genes in the true list to get the false-discovery rate. Moreover, functional analysis was performed on the up-and down-regulated genes using the freely available Expression Analysis Systemic Explorer (EASE) software [19] to identify functional groups, gene ontology categories and/or pathways that may be over-represented.
Results
KM12C, KM12SM and KM12L4a Treated with SN-38 in a Microarray Analysis
The 3 human colon cancer cell lines, KM12C, KM12SM and KM12L4a, were treated with topo-1 inhibitor SN-38 at a dose of 2.5 g/ml for 24 and 48 h.
Oligonucleotide microarray slides comprising of ϳ 27,000 spots were used for the expression analysis, and ϳ 5,900 genes remained for the analysis after the application of various filters and transformation steps. The unsupervised hierarchical clustering performed on these 5,900 genes is shown in figure 1 a and clearly splits the treated samples from the untreated ones. Golub-score analysis identified 3,974 (p = 0.05) genes that differed in expression levels between the 6 treated and the 6 untreated cell lines. In order to group the genes based on their functional classification, the EASE functional analysis tool was used. The data retrieved from the Golub-score analysis (cut-off value p ^ 0.05), where genes were divided into up-and down-regulated ones, were further explored with EASE analysis which resulted in 5 main functional groups among the down-regulated genes ( table 1 ): RNA synthesis/RNA metabolism/RNA processing/RNA modification/RNA splicing/RNA binding; protein synthesis/protein metabolism/chromosome/nuclear and cell biogenesis and organization; protein transport/nuclear and cell biogenesis and organization; cell cycle, and DNA metabolism/chromosome/nuclear biogenesis and organization. Up-regulated genes were restricted to 4 main functional Organismal role General cellular role 26
Subcellular localization Nuclear 232
Functional groups: 1 = RNA synthesis, metabolism, processing, modification, splicing and binding; 2 = protein synthesis, protein metabolism, chromososme, nuclear and cell biogenesis and organization; 3 = protein transport, nuclear & cell biogenesis & organization; 4 = cell cycle; 5 = DNA metabolism, chromosome and nuclear biogenesis and organization. 
Top Scores of Down-and Up-Regulated Genes
Among the down-regulated genes, the Golub-score range for the top 10 down-regulated genes was from 5.34
(IBTK) to 6.63 (DOK6) ( table 3 ). Of these 10 genes the majority of them were involved in cell proliferation, RNA processing and apoptosis.
All up-regulated genes were listed in the correspondence to their Golub-score. The 10 genes with the highest Golub-scores in the list were selected for further evaluation ( table 4 ) . The gene SGK (SGK-1) was found to be of highest significance, with a Golub-score of 6.48, and TXNIP had the lowest score (4.22) . Among the highly expressed genes, some were involved in apoptosis, e.g. SGK, RHOB and BAX . Another major groups consists of genes involved in transcription (SERTAD1 and ZNF26) , and in development and differentiation (HMX1 and ADM) .
Discussion
SN-38, as an active metabolite of topo-1 inhibitor irinotecan, binds to topo-1 and stabilizes thereby the cleavable complexes. This leads to ssDNA breaks that are subsequently converted into dsDNA breaks. Thus, cell cycle arrest is induced due to the impaired DNA processing and, as a consequence, cell death is executed.
In our previous study, we treated colon cancer cell lines KM12C, KM12SM and KM12l4a with SN-38, and found that S phase and G2 arrest were induced together with increased apoptotic cell death, increased Bax protein expression and decreased topo-I protein expression [12] . In the present study, we further examined the gene expression profile of the same cell lines treated with SN-38. Analyses of the functional groups of the genes showed that apoptosis-associated genes were highly affected by SN-38 in both down-and up-regulated genes. The majority of the genes (1,036) were down-regulated and only 417 genes were up-regulated.
Among the down-regulated genes, DOK6 was on the top of the gene list, a gene that interacts with proto-oncogene RET . In thyroid carcinoma xenografts, inhibition of RET significantly increased the apoptotic response. IBtk was another down-regulated gene, and it functions as an inhibitor to Btk and subsequently as an inhibitor of NF B-driven transcription [20] . Over-expression of the proto-oncogene K-ras is frequent in CRC and associated with, for example, a high proliferative state [21] . After SN-38 treatment, K-ras expression was down-regulated, although with low significance (Golub-score ! 3). Moreover, an under-expression of survivin (BIRC5) was detected, also with a Golub-score ! 3, indicating low significance. Survivin, as a member of the inhibitor of apoptosis (IAP) family, blocks the apoptotic process by inhibiting 
Biochemical function
Inhibitor or repressor 57
Functional groups: 1 = receptor activity/signal transduction/cell communication; 2 = development and differentiation; 3 = immune response; 4 = transporters/channels. primarily caspases 3 and 7 and is proposed as a target for drug therapies due to its limited expression in tumour cells [22] .
Of the up-regulated genes based on the Golub-score, the top 4 genes (SGK , PHLDA2 , IER3 , and RhoB) are all implicated in apoptosis. For example, RhoB , a member of the RAS superfamily and which functions as a tumour suppressor [23] , was highly ranked. Also ranked highly was IER3 , which through the inhibitory effect of NF B [24] also plays the role of tumour suppressor. Further pro-apoptotic Bax was also found to be up-regulated, as was I BB (NF BIB) , an inhibtor to NF B [25] . Up-regulation of Bax after SN-38 treatment has been previously demonstrated [26, 27] , and over-expression of protein Bax has also been favourable in the way it enhances the induction of apoptosis [28] .
Some genes were down-or up-regulated after the SN-38 treatment, in an opposite manner to that expected. For example, WT1 ( PAWR ) was down-regulated, although it functions as a tumour suppressor in the way it represses transcription, along with the function of an apoptosis inducer via Bak [29] .
Taken together, the genes involved in cell proliferation and apoptosis seem to be affected by SN-38 in a positive manner, i.e. promoting cell cytotoxicity. The status of tumour suppressor p53 is widely implicated in the success of chemotherapy [30] , mainly through its role in apoptosis. The 3 cell lines in this study, KM12C, KM12SM and KM12L4a, are p53 mutated [31] . It is postulated that 2 different events could occur after SN-38 treatment depending on the p53 status. For p53 wild-type cells, cellular senescence is induced via S/G2 arrest that subsequently becomes permanent, compared to p53 mutated cells which will suffer from mitotic catastrophe and apoptosis [32, 33] . This corresponds with the results of altered expressions of apoptosis-associated genes here described. It is widely discussed whether the expression of topo-1 is altered following SN-38 treatment. In this study no such evidence of change in RNA expression after SN-38 treatment could be found and this was consistent with other findings [8, 27, 33] . The response to irinotecan is perhaps independent of topo-1 expression [34] . Although in our previous study, topo-1 protein expression was found to be down-regulated following SN-38 treatment [12] . Changes in RNA expression do not necessarily have to have a direct impact on the protein expression. It could be possible that the deviant expression derives from posttranscriptional or translational alterations.
It is noteworthy that the cell lines display very similar gene expression profiles. From the parental cell line KM12C, two metastatic cell lines, KM12SM and KM12 L4a, were established. Even though the ability to form metastasis may vary between the cell lines, the response to the drug SN-38 is similar, indicating a nonsignificant influence on the metastasis-related factors. In our earlier study, different protein expression levels were detected depending of the metastatic potential [12] . However, in this current study all samples were analysed together for the gene expression profile and not as individual samples. In other words, the exact expression of each cell line could not be detected. Therefore, it is required that the expression of certain genes are analysed for each specific cell line.
In conclusion, the present results indicate that the expression of the genes involved in cell proliferation and apoptosis was affected by SN-38, based on their RNA expression. The impact of certain genes on CRC development needs to be further investigated; however, these results could serve as a basis for further studies in order to find targets for irinotecan treatment.
